StockData

VolitionRx vs Xenetic Biosciences

VNRX and XBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How VNRX and XBIO compare

Xenetic Biosciences is the larger company, worth 1.3 times as much as VolitionRx ($3.5M against $2.7M).

VolitionRx grew revenue faster over the last twelve months (86.3% versus 33.3% for Xenetic Biosciences).

Xenetic Biosciences keeps more of each dollar of sales as profit, with a net margin of −75.9% compared with −1043% at VolitionRx.

Xenetic Biosciences scores higher on the StockData Score (12 against 4 for VolitionRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricVNRXXBIO
Size and price
Market cap$2.7M$3.5M
Share price$0.200$1.49
Change, 1 year−97.2%−42.0%
Change, 5 years−99.7%−89.8%
Beta (5Y)2.191.24
Employees752
StockData Score
Total score412 (better)
Valuation score13 (better)
Growth score22
Performance score12 (better)
Health score05 (better)
Dividend score00
Valuation
P/S1.1×1.1× (better)
P/B–0.6×
FCF yield−718%–
Fair value–$4.58
Margin of safety–67.5%
Growth
Revenue growth (TTM)86.3% (better)33.3%
Revenue growth, 5Y average164% (better)46.8%
Profitability
Operating margin−790%−81.0% (better)
Net margin−1043%−75.9% (better)
FCF margin−797%–
Return on equity–−47.0%
Financial health
Debt / equity–0.00
Current ratio0.307.43 (better)
Altman Z-score−53.84−37.89 (better)
Piotroski F-score25 (better)
Dividends and buybacks
Buyback yield−709%–
Shareholder yield−709%0.00% (better)
Ownership
Held by institutions14.1%6.5%
Held by insiders–12.2%
Insider net buying, 12 months$0–
Short interest, % of float–1.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.